Search results
Results from the WOW.Com Content Network
Acral erythema is a common adverse reaction to cytotoxic chemotherapy drugs, particularly cabozantinib, cytarabine, doxorubicin, and fluorouracil and its prodrug capecitabine. [3] Targeted cancer therapies, especially the tyrosine kinase inhibitors sorafenib and sunitinib, have also been associated with a high incidence of acral erythema ...
Necrolytic acral erythema can show clinically as either acute or chronic. Flaccid blisters, erosions at the margins, and noticeable erythema are the symptoms of acute lesions. The hyperkeratotic surface, moderate erythema, and dark red border are seen in the chronic lesions. Edema may be present in conjunction. [4]
Erythema toxicum neonatorum (erythema toxicum, toxic erythema of the newborn) Granuloma faciale; Hypereosinophilia; Hypereosinophilic syndrome; Incontinentia pigmenti (Bloch–Siemens syndrome, Bloch–Sulzberger disease, Bloch–Sulzberger syndrome) Itchy red bump disease (papular dermatitis) Juvenile xanthogranuloma; Kimura's disease
Necrolytic migratory erythema (NME) is a red, blistering rash that spreads across the skin. It particularly affects the skin around the mouth and distal extremities; but may also be found on the lower abdomen, buttocks, perineum , and groin.
Peeling skin syndrome in the legs and feet. Peeling skin syndrome (also known as acral peeling skin syndrome, continual peeling skin syndrome, familial continual skin peeling, idiopathic deciduous skin, and keratolysis exfoliativa congenita [1]) is an autosomal recessive disorder characterized by lifelong peeling of the stratum corneum, and may be associated with pruritus, short stature, and ...
Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group. [3]: 129 These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome.
The symptoms of DRESS syndrome usually begin 2 to 6 weeks but uncommonly up to 8–16 weeks after exposure to an offending drug. Symptoms generally include fever, an often itchy rash which may be morbilliform or consist mainly of macules or plaques, facial edema (i.e. swelling, which is a hallmark of the disease), enlarged and sometimes painful lymph nodes, and other symptoms due to ...
TEN is a type of severe cutaneous adverse reactions (SCARs), together with SJS, a SJS/TEN, and drug reaction with eosinophilia and systemic symptoms. [5] It is called SJS when less than 10% of the skin is involved and an intermediate form with 10 to 30% involvement. [3] Erythema multiforme (EM) is generally considered a separate condition. [6]